JP Morgan Notebook Day 1 Pfizer Gilead Alnylam Novartis Sarepta Deal Trends And Cell Therapy Challenges

JP Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

21:39 EST 7 Jan 2019 | SCRIP

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation...